Dr. Reddy’s: FY26 Growth Meets Pipeline and Margin Reset

Transcript intelligence

What changed

The current call added a large lenalidomide shelf-stock adjustment as a near-term headwind, while highlighting semaglutide approvals in Canada and India, progress toward an abatacept biosimilar launch, and an expected FY27 gross-margin improvement above 50%.

Guidance delta

Management guidance sentiment was maintained. Management expects gross margin to improve to above 50% in FY27, while SG&A and capex are expected to remain roughly at FY26 levels.

Key takeaways

• The base business delivered double-digit growth, but a large lenalidomide shelf-stock adjustment weighed on adjusted Q4 revenue.
• Management expects gross margin to improve above 50% in FY27 as product mix shifts and price erosion eases.
• Semaglutide approvals in Canada and India, including an oral formulation, expand a potential growth franchise; Brazil approval remains pending.
• Abatacept biosimilar progress and the NRT consumer-health acquisition are central to the next phase of growth.

Management priorities

• Expand semaglutide across additional markets and qualify more pen manufacturing capacity.
• Advance abatacept and denosumab biosimilars through regulatory review and commercialization.
• Complete NRT integration and build organic growth in consumer health.
• Maintain disciplined SG&A and capex while supporting the product pipeline.